NeRRe Therapeutics is developing orvepitant, a neurokinin (NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders. Having demonstrated proof of efficacy in patients with refractory or unexplained cough, NeRRe will now continue development in chronic cough caused by the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF). A dominant feature of this severe progressive respiratory disease in a high proportion of patients is an uncontrolled and persistent cough which is disabling for these terminally ill patients. The cough is often refractory to medical therapy and there are no approved treatments. Idiopathic pulmonary fibrosis has been designated an orphan disease in both Europe and the USA.
Location: United Kingdom, England, Stevenage
Employees: 11-50
Total raised: $56.22M
Founded date: 2012
Investors 4
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | OrbiMed | orbimed.co... |
| - | Advent Lif... | adventls.c... |
| - | Fountain H... | fh-partner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.07.2021 | Series B | $27.65M | - |
| 05.01.2017 | Series B | $28.57M | Forbion |
Mentions in press and media 10
| Date | Title | Description | Source |
| 07.07.2021 | NeRRe Therapeutics raises £20 million in a Series B2 finan... | NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (N... | fh-partner... |
| 07.07.2021 | NeRRe Therapeutics raises £20 million in a Series B2 financi... | Stevenage, UK, 7 July 2021 – NeRRe Therapeutics, a clinical-stage company developing orvepitant, its... | forbion.co... |
| 07.07.2021 | NeRRe Therapeutics raises £20 million in a Series B2 financi... | NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitan... | marketscre... |
| 07.07.2021 | NeRRe nabs £20M to test chronic cough drug in patients with ... | Patients who have the rare and fatal lung disorder idiopathic pulmonary fibrosis (IPF) have an uncon... | medcitynew... |
| 05.01.2017 | GSK spinout bags £23M to take NK antagonists into phase 2 | NeRRe Therapeutics has raised £23 million ($28 million) in a Series B backed by new investors Founta... | fiercebiot... |
| 05.01.2017 | Term Sheet — Thursday, January 5 | THE 21 BEST TECH IPOS of 2016, ETC Visions: SoftBank has been purposely opaque about many aspects o... | fortune.co... |
| 05.01.2017 | Forbion Announces - NeRRe Therapeutics raises £23 million in... | NeRRe Therapeutics (‘NeRRe’), a clinical-stage company developing a unique portfolio of neurokinin (... | forbion.co... |
| 05.01.2017 | Pieris soars on $31M-plus checkpoint development deal; L... | • Boston-based Pieris $PIRS has inked a deal to work with France’s Servier on some bispecific ch... | endpts.com... |
| 05.01.2017 | NeRRe Therapeutics Raises £23M in Series B Financing | NeRRe Therapeutics, a Stevenage, England, UK-based clinical-stage company, raised £23m in Series B f... | finsmes.co... |
| - | NeRRe nabs £20M to test chronic cough drug in patients with ... | Patients who have the rare and fatal lung disorder idiopathic pulmonary fibrosis (IPF) have an uncon... | medcitynew... |